A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 308,000 shares of SRPT stock, worth $32.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
308,000
Previous 386,100 20.23%
Holding current value
$32.2 Million
Previous $61 Million 36.94%
% of portfolio
0.01%
Previous 0.01%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$124.33 - $156.75 $18.7 Million - $23.6 Million
150,398 Added 19.39%
926,219 $116 Million
Q2 2024

Aug 14, 2024

SELL
$113.33 - $163.85 $84.7 Million - $122 Million
-747,256 Reduced 49.06%
775,821 $123 Million
Q1 2024

May 15, 2024

BUY
$93.7 - $141.53 $16.9 Million - $25.5 Million
180,347 Added 13.43%
1,523,077 $197 Million
Q4 2023

Feb 14, 2024

BUY
$67.31 - $124.76 $7.72 Million - $14.3 Million
114,756 Added 9.35%
1,342,730 $129 Million
Q3 2023

Nov 14, 2023

BUY
$102.5 - $123.59 $34.6 Million - $41.7 Million
337,261 Added 37.86%
1,227,974 $149 Million
Q2 2023

Aug 14, 2023

BUY
$106.4 - $157.19 $67.8 Million - $100 Million
637,299 Added 251.49%
890,713 $102 Million
Q1 2023

May 15, 2023

SELL
$117.53 - $155.99 $17.9 Million - $23.7 Million
-152,067 Reduced 37.5%
253,414 $34.9 Million
Q4 2022

Feb 14, 2023

BUY
$100.86 - $132.13 $30.6 Million - $40.1 Million
303,359 Added 297.06%
405,481 $52.5 Million
Q3 2022

Nov 14, 2022

SELL
$75.71 - $119.24 $35.7 Million - $56.2 Million
-471,201 Reduced 82.19%
102,122 $11.3 Million
Q2 2022

Aug 15, 2022

SELL
$62.69 - $88.44 $1.38 Million - $1.94 Million
-21,965 Reduced 3.69%
573,323 $43 Million
Q1 2022

May 16, 2022

BUY
$63.15 - $90.42 $17.6 Million - $25.2 Million
278,861 Added 88.13%
595,288 $46.5 Million
Q4 2021

Feb 14, 2022

SELL
$77.28 - $99.42 $35.2 Million - $45.3 Million
-455,377 Reduced 59.0%
316,427 $28.5 Million
Q3 2021

Nov 15, 2021

BUY
$65.97 - $92.48 $3.92 Million - $5.5 Million
59,445 Added 8.34%
771,804 $71.4 Million
Q2 2021

Aug 16, 2021

BUY
$69.38 - $86.75 $32.4 Million - $40.5 Million
466,488 Added 189.73%
712,359 $55.4 Million
Q1 2021

May 17, 2021

BUY
$72.25 - $168.95 $16.5 Million - $38.7 Million
228,789 Added 1339.36%
245,871 $18.3 Million
Q4 2020

Feb 16, 2021

SELL
$125.56 - $178.74 $15.3 Million - $21.8 Million
-122,029 Reduced 87.72%
17,082 $2.91 Million
Q3 2020

Nov 16, 2020

BUY
$127.12 - $172.34 $9.57 Million - $13 Million
75,309 Added 118.04%
139,111 $19.5 Million
Q2 2020

Aug 14, 2020

SELL
$93.0 - $171.7 $6.37 Million - $11.8 Million
-68,500 Reduced 51.78%
63,802 $10.2 Million
Q1 2020

May 15, 2020

BUY
$82.38 - $131.64 $4.17 Million - $6.66 Million
50,585 Added 61.9%
132,302 $12.9 Million
Q4 2019

Feb 14, 2020

SELL
$76.53 - $135.58 $19.1 Million - $33.9 Million
-249,913 Reduced 75.36%
81,717 $10.5 Million
Q3 2019

Nov 14, 2019

BUY
$72.81 - $156.91 $23 Million - $49.6 Million
316,262 Added 2057.93%
331,630 $25 Million
Q2 2019

Aug 14, 2019

SELL
$112.21 - $151.95 $17.4 Million - $23.6 Million
-155,342 Reduced 91.0%
15,368 $2.34 Million
Q1 2019

May 15, 2019

BUY
$106.67 - $151.68 $17.9 Million - $25.4 Million
167,483 Added 5190.05%
170,710 $0
Q4 2018

Feb 14, 2019

SELL
$97.32 - $148.76 $27.6 Million - $42.2 Million
-283,984 Reduced 98.88%
3,227 $352,000
Q3 2018

Nov 13, 2018

SELL
$115.31 - $161.51 $17.4 Million - $24.4 Million
-151,103 Reduced 34.47%
287,211 $0
Q2 2018

Aug 10, 2018

BUY
$71.74 - $153.69 $28 Million - $59.9 Million
389,927 Added 805.85%
438,314 $0
Q1 2018

May 11, 2018

SELL
$54.02 - $82.27 $21.7 Million - $33 Million
-401,315 Reduced 89.24%
48,387 $3.59 Million
Q4 2017

Feb 09, 2018

SELL
$47.64 - $56.75 $75.5 Million - $90 Million
-1,585,488 Reduced 77.9%
449,702 $25 Million
Q3 2017

Nov 09, 2017

BUY
$35.73 - $47.15 $72.7 Million - $96 Million
2,035,190
2,035,190 $92.3 Million

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.15B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.